兔抗EIF4G1 (phospho-Ser1232)多克隆抗體

Background:

eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis

Applications:

WB, IHC

Name of antibody:

EIF4G1 (phospho-Ser1232)

Immunogen:

Synthetic peptide of human EIF4G1 (phospho-Ser1232)

Full name:

eukaryotic translation initiation factor 4 gamma, 1 (phospho-Ser1232)

Synonyms：

P220; EIF4F; EIF4G; EIF4GI; PARK18; EIF-4G1

SwissProt:

G5E9S1

IHC positive control:

Human lung carcinoma

IHC Recommend dilution:

50-100

WB Predicted band size:

220 kDa

WB Positive control:

HT29 cells treated with Anisomycin

WB Recommended dilution:

500-1000